Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers
Relative Bioavailability Study of an Extended Release (ER) Tablet Formulation of MN-166 (Ibudilast) Compared to an Intermediate Release (IR) Capsule Formulation in Healthy Volunteers
Sponsor: MediciNova
This PHASE1 trial investigates Healthy Volunteers and is currently completed. MediciNova leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 3 earlier versions
-
Feb 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE1
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
Sep 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE1
First recorded
Jun 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MediciNova
For direct contact, visit the study record on ClinicalTrials.gov .